Cardiol Therapeutics Inc Class A (CRDL)

Name: Cardiol Therapeutics Inc Class A (CRDL) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Cardiol Therapeutics Inc Class A (CRDL)

Stock Card

$2.14

$-0.03 (-1.16%)

As on 04-Sep-2026 13:39EDT

Market cap

$227 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

13.9

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Cardiol Therapeutics Inc Class A (CRDL) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.13 High: 2.17

52 Week Range

Low: 0.88 High: 2.28

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.9 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.3
Debt to Equity

0
Book Value

$--
EPS

$-0.4
Face value

--
Shares outstanding

116,822,671

7 Years Aggregate

CFO

CA$-108.70 Mln

EBITDA

CA$-167.55 Mln

Net Profit

CA$-142.58 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Cardiol Therapeutics Inc Class A (CRDL)	123.8	63.0	90.6	95.9	28.8	-11.0	--
BSE Sensex	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020
Cardiol Therapeutics Inc Class A (CRDL)	-25.5	65.3	-72.4	-33.5	-39.3
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6
BSE Sensex	9.1	18.7	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Cardiol Therapeutics Inc Class A (CRDL)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III... multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Read more

President, CEO & Director

Mr. David G. Elsley MBA
President, CEO & Director

Mr. David G. Elsley MBA
Headquarters

Oakville, ON
Website

https://www.cardiolrx.com

FAQs for Cardiol Therapeutics Inc Class A (CRDL)

What is the current share price of Cardiol Therapeutics Inc Class A (CRDL) Today?

The share price of Cardiol Therapeutics Inc Class A (CRDL) is $2.14 (NASDAQ) as of 04-Sep-2026 13:39 EDT. Cardiol Therapeutics Inc Class A (CRDL) has given a return of 28.77% in the last 3 years.

What is the current PB & PE ratio of Cardiol Therapeutics Inc Class A (CRDL)?

Since, TTM earnings of Cardiol Therapeutics Inc Class A (CRDL) is negative, P/E ratio is not available.
The P/B ratio of Cardiol Therapeutics Inc Class A (CRDL) is 13.86 times as on 28-Aug-2026, a 250 premium to its peers’ median range of 3.96 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-2.83	5.35
2024	-2.44	3.62
2023	-2.60	1.95
2022	-1.43	0.85
2021	-4.21	1.38

What is the 52 Week High and Low of Cardiol Therapeutics Inc Class A (CRDL)?

The 52-week high and low of Cardiol Therapeutics Inc Class A (CRDL) are Rs 2.28 and Rs 0.88 as of 05-Sep-2026.

What is the market cap of Cardiol Therapeutics Inc Class A (CRDL)?

Cardiol Therapeutics Inc Class A (CRDL) has a market capitalisation of $ 227 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Cardiol Therapeutics Inc Class A (CRDL)?

Before investing in Cardiol Therapeutics Inc Class A (CRDL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.